Press Releases

Aspen’s profit after tax increases by 35%

Aspen’s profit after tax increases by 35% Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical manufacturer in the southern hemisphere, has announced pleasing results for the six months ended 31 December 2015. The Group delivered solid growth in a period marked by economic stress and weakening market currencies. The factors set out below have significantly affected the comparability of the results with those of the prior period: The completion on 31 August 2015 of the divestment of the generics business conducted in Australia as well as certain branded products distributed in Australia to Strides group companies, the related termination of license arrangements in Australia and the completion on 1 October 2015 of the divestment of a portfolio of products distributed in South Africa to Litha Pharma (collectively “the Divestments”). The Divestments gave rise to a pre-tax profit on disposal of R1.7 billion. However, as a consequence of the timing of these transactions, the contribution to the trading results by the Divestments is substantially reduced in the current period. In the period from 1 July 2015 until the effective date of divestment, revenue from the Divestments was R202 million whereas revenue from the Divestments for the six months ended 31 December 2014 was R1 148 million. The economic situation in Venezuela deteriorated over the 6 months to December 2015 and the Venezuelan authorities have increasingly limited authorisations to pay for pharmaceutical imports using the official CENCOEX rate during this period of Venezuelan Bolivars (“VEF”) 6.30 per US Dollar (“USD”). As a consequence of the limited payment approvals and the uncertain economic and political situation in Venezuela, the Group has concluded that it would be more appropriate to apply the SIMADI exchange rate of VEF 200 per USD to report the Venezuelan business’ financial position, results of its operations and cash flows for the 6 months ended 31 December 2015. This has resulted in a one-off currency devaluation loss on foreign denominated liabilities of R841million. The profit arising from the Divestments, the currency devaluation loss and the hyperinflationary adjustments relating to Venezuela are excluded in determining normalised headline earnings per share (“NHEPS”) which increased by 14%. In order to provide meaningful comparability of the financial performance of the ongoing underlying business, a measure described as comparable NHEPS has been determined by removing the contribution by the Divestments from NHEPS and including the results of Aspen’s business in Venezuela translated at VEF 200 per USD in the prior reporting period. Comparable NHEPS for the 6 months ended 31 December 2015 was 640,9 cents, an increase of 21%. Applying the same principles, comparable revenue increased by 8% and comparable operating profit increased by 8%. GROUP PERFORMANCE Revenue excluding the effect of the Divestments, increased by 8% to R 17.3 billion. Profit after tax increased 35% to R3.3 billion. Comparable normalised headline earnings per share increased by 21% to 640,9 cents. Normalised headline earnings per share improved by 14% to 655.5 cents. Borrowings, net of cash, increased R3.5 billion over the period to R33.5 billion. Group operating cash flows were negatively affected by a R1.8 billion increase in working capital over the period. Stephen Saad, Aspen Group Chief Executive said, “Performance was led by the International business where the Europe CIS region made a strong contribution. The nutritional products in South Africa and in Asia Pacific also achieved good growth. The completion of the Divestments marks an important step in achieving increased focus in the South African and Asia Pacific businesses. Further meaningful advances in the implementation of Aspen’s strategic objectives have been made and we are seeking to grow the business in targeted therapeutic categories. We remain alert to opportunities to expand our product portfolio in these areas of focus.” INTERNATIONAL BUSINESS The International Business improved revenue 2% to R9.0 billion and raised operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), 16% to R2.8 billion. Revenue was unfavourably affected by R836 million due to the devaluation of the Venezuelan contribution. Excluding the effect of the devaluation, revenue increased 14% in the remainder of the International business. Revenue from customers in Europe and the Commonwealth of Independent States (“Europe CIS”) increased 21% to R6.1 billion. Finished dose form pharmaceutical sales to healthcare providers were up 20% to R4.1 billion. The acquisition of Mono-Embolex, with almost all of its sales in Germany, in the second half of the previous year further strengthened Aspen’s offering in this therapeutic area and added to growth. However, the contribution from Russia fell sharply due to the significant weakening of the Ruble. API sales continued to grow and were the largest part of the balance of the revenue from Europe CIS. Sales to customers in Latin America (excluding Venezuela) declined by 1% to R1.7 billion, unfavourably influenced by difficult socio-economic conditions in Brazil. The nutritionals products in the region maintained their positive growth momentum with revenue rising 12%. Demand for Aspen’s pharmaceutical products was strong, but performance has continued to be suppressed by unreliable supply of certain key products by contract manufacturers. The devalued contribution from Venezuela is no longer material to the Group.| Sales to customers in the Rest of the World increased 4% to R922 million, led by a positive performance in the Middle East North Africa territory. The installation of a new high-speed pre-filled syringe filling line at Aspen Notre Dame de Bondeville (“Aspen NDB”) was completed during the period and commercial production is about to commence. At Aspen Oss capital expenditure projects are ongoing, focused on the sustainability of the site. SOUTH AFRICAN BUSINESS In the South African business revenue was 3% lower at R4.2 billion. Excluding the effect of the Divestments, revenue improved by 4%. The nutritionals products were the leading performer, with revenue growing 15% to R402 million. In the balance of the private sector, branded and generic pharmaceuticals performed satisfactorily. However, supply problems severely undermined the performance of the over-the-counter (“OTC”) products with a consequential decline in key OTC brands. Sales in the public sector (excluding

Aspen’s revenue increases 22% to R36 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the sixth largest generic company in the world, has announced excellent results for the year ended 30 June 2015. These results benefitted from the contribution of acquisitions concluded during the prior year. GROUP PERFORMANCE Revenue increased by 22% to R36.1 billion. Operating profit rose by 14% to R8.4 billion. Normalised headline earnings, being headline earnings adjusted for specific non-trading items, increased by 15% to R5.6 billion. Normalised headline earnings per share improved by 15% to 1 219 cents. Borrowings, net of cash, increased R0.2 billion to R30.0 billion. R2.5 billion of this arose from unfavourable relative foreign exchange rate movements. Group operating cash flows remained strong and cash generated from operating activities increased by 26% to R4.8 billion. A capital distribution of 216 cents per ordinary share was declared. Stephen Saad, Aspen Group Chief Executive said, “The excellent results were led by the International business which remained the largest contributor to the Group, delivering 49% of gross revenue. Sales in Asia jumped 39% to R1.3 billion due to a combination of organic growth and recent acquisitions led by strong advances in Japan. The results were achieved despite an unfavourable exchange rate environment affecting the Group’s principal trading currencies, particularly relative to the US Dollar, which resulted in a devaluing of revenue flows and an increase in cost of goods. INTERNATIONAL BUSINESS In the International business, revenue climbed 46% to R18.6 billion and operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), advanced 42% to R5.2 billion. The International business performance was assisted by the inclusion of the significant transactions completed during the prior year and contributed more than half of Group EBITA. The disposal of the rights to commercialise the fondaparinux products (being Arixtra and the authorised generic thereof) in the United States to Mylan, for a consideration of USD 300 million, became effective during the first half of the 2015 financial year with the consequential loss of contribution. Revenue from customers in Europe and the Commonwealth of Independent States (“Europe CIS”) increased 45% to R10.5 billion. Finished dose form pharmaceutical sales to healthcare providers comprised R6.9 billion of the total sales. The acquisition in the second half of the year of Mono-Embolex, an anti-coagulant with almost all of its sales in Germany, further strengthened Aspen’s offering in this therapeutic area. The largest part of the balance of the sales in the region was from active pharmaceutical ingredient (“API”) sales. Relative weakness of the Europe CIS currencies to the Rand reduced reported revenue from this region. Sales to customers in Latin America (excluding Venezuela) grew 44% to R3.4 billion, supported by the infant nutritionals acquisition in the prior year. Performance was constrained due to poor supply by contract manufacturers of certain key pharmaceutical products. In Venezuela, sales to customers were up 143% to R2.7 billion. The results in Venezuela have been influenced by the application of hyper inflationary accounting principles and a change in the rate of exchange applied in the translation of local currency results from the prior year. The net effect of these entries on EBITA is not significant. Sales to customers in the Rest of the World were down 10% to R1.6 billion, influenced by the disposal of the fondaparinux products for the United States to Mylan. Capital expenditure projects remain underway in the Netherlands at Aspen Oss (Netherlands) and in France at Aspen Notre Dame de Bondeville (“Aspen NDB”). At Aspen Oss, the projects are focused on the repurposing of facilities and at Aspen NDB, the addition of a new pre-filled syringe filling line is well advanced. SOUTH AFRICAN BUSINESS Revenue in the South African business increased by 16% to R8.6 billion. Private sector pharmaceutical sales improved 12% through a combination of organic growth and new product launches. Public sector sales grew 14% led by demand under the antiretroviral (“ARV”) tender. The consumer division raised revenue by 23% due to a strong performance from infant nutritionals, with Infacare making impressive gains in its share of this category. Revenue from manufacturing for third parties also showed a good increase. The increase in the ARV tender revenue coupled with the ongoing weakening of the Rand relative to the US Dollar and high wage and energy cost inflation has placed pressure on EBITA margins. Expansion projects continued at the Port Elizabeth finished dosage form manufacturing site and at the API manufacturing site in Cape Town (“Fine Chemicals”). In Port Elizabeth, the building of the high containment facility is nearing completion and manufacturing trials in the hormonal suite have commenced. The packing facility upgrade is complete. Construction of the additional specialist sterile manufacturing facility has commenced. At Fine Chemicals, production is underway in certain of the newly constructed suites, while other parts of this expansion and upgrade project remain in progress. ASIA PACIFIC BUSINESS Revenue in the Asia Pacific business was 5% lower at R8.1 billion and EBITA declined by 10% to R1.7 billion. In Australasia sales to customers were 8% lower at R7.2 billion. The key focus areas of branded pharmaceuticals and infant nutritionals both showed positive growth. This was, however, reversed by the effect of disposals as well as the termination of licenses and contract manufacturing arrangements in the second half of the prior financial year. These were undertaken in accordance with the strategy to achieve greater focus in this business. Cost of goods in Australia increased due to the weakening of the Australian Dollar against the US Dollar in which many input costs are denominated. Sales to customers in Asia accelerated by 39% to R1.3 billion through a combination of organic growth and recent acquisitions, led by strong advances in Japan. SUB-SAHARAN BUSINESS In Sub-Saharan Africa, revenue was 1% higher at R2.8 billion. A disappointing performance from the GSK Aspen Healthcare for Africa Collaboration, which was hampered by supply problems, limited performance in the region. Weakening in-market currencies contributed to narrowing margins and a reduction of 6% in EBITA to R313 million. PROSPECTS Strategically, the

Divestment of portfolio of branded and generic products to Strides entities

Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma Pty Ltd (“Strides Australia”), a company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a portfolio of approximately 130 products for a consideration of approximately A$265 million (“the Australian Transaction”). The portfolio of products in the Australian Transaction comprises a generic pharmaceutical business together with certain branded pharmaceutical assets. This portfolio recorded revenue of A$106 million and a direct contribution to profit before tax of A$26 million for the year ended 30 June 2014. In a separate transaction, Aspen Global Incorporated (“AGI”), a company incorporated in Mauritius, has entered into an agreement with Strides Pharma Global Pte Limited (“Strides Singapore”), a company incorporated in Singapore, in terms whereof AGI will divest to Strides Singapore, a portfolio of six branded prescription products, for a consideration of approximately US$92 million. This portfolio recorded revenue of US$12 million and a direct contribution to profit before tax of US$10 million for the year ended 30 June 2014. Strides Australia and Strides Singapore are wholly owned subsidiaries of Strides Arcolab Limited (“Strides”), a pharmaceutical company headquartered and publicly listed in India. Strides have a key focus on the development and manufacture of IP-led, niche pharmaceuticals products. These transactions form part of Aspen’s communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity. The transactions are conditional upon, inter alia, the approval of the Australian Foreign Investments Review Board. Durban 21 May 2015 Sponsor: Investec Bank Limited ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen” or “the Group”)

Cautionary Announcement

Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the Company’s securities. Durban 14 May 2015 Sponsor Investec Bank Limited

Divestment of South African Business Unit to Litha

Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of Aspen Holdings and the Group’s primary South African trading company, has concluded a set of agreements with Litha Pharma (Pty) Ltd (“Litha”) (a wholly owned South African subsidiary of Endo International Plc) in terms which Pharmacare will divest a business unit which forms part of its pharmaceutical division to Litha for a consideration of approximately R1.6 billion (“the Transaction”). The business unit concerned has a product portfolio comprising injectables and established brands. This portfolio recorded revenue of R362 million and a direct contribution to profit before tax of R136 million for the year ended 30 June 2014. The Transaction forms part of Aspen’s communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity. The Transaction is conditional upon, inter alia, the approval of the South African Competition Authorities. Durban 11 May 2015 Sponsor: Investec Bank Limited

Gauteng Premier’s visit to Aspen is set to boost export growth

Clayville, Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the 5th largest generic company in the world, earlier today hosted a delegation of over 30 government dignitaries at its manufacturing facility where specialised infant nutritional products are produced for local and export markets. The facility is unique in that it contains highly specialized spray dried capability which enables the manufacture of some of the continent’s leading Infant Milk Formula (IMF) brands such as Infacare, Infacare Gold and the S-26 range. Aspen recently acquired the S-26 portfolio from Nestlé. The delegation was led by Gauteng Premier David Makhura and the Minister of Agriculture, Forestry and Fisheries Senzeni Zokwana, and included Gauteng MEC for Health Qedani Mahlangu and Ekurhuleni Mayor Mondli Gungubele. Government expressed their approval of Aspen’s commitment to the enhancement of local manufacturing, which significantly contributes to provide for increased economic growth and export opportunities in the province. Aspen’s range of IMFs has been earmarked for strategic export markets such as sub-Saharan Africa (SSA) and China. Stephen Saad, Aspen Group Chief Executive reiterated the Group’s global expansion into various markets including Africa, Europe, South America and Asia. “Aspen has successfully created a business presence on 6 continents and our previously stated objective of increasing our footprint in the Asian and SSA markets is rapidly materializing. China is a key growth area for the Group and its burgeoning population offers significant export opportunities for our infant nutritional and other locally manufactured products”. Saad said that the Group remained committed to South African economic development through ongoing investment in its manufacturing facilities. A key component of the IMF is the base powder that is currently imported. There are however opportunities for local agro processing of the base powder which will build value linkages across communities, provide a much needed economic boost and also curtail raw manufacturing costs which will result in enhanced competitiveness in export markets. He announced that a further capex has been earmarked for investment at the Aspen Nutritionals site in Clayville in order to increase manufacturing capacity for export markets. The investment would however be dependent upon various factors including local supply, competitive pricing and the review of tariffs on imported blended powder. “Aspen Nutritionals is one of very few facilities that has invested in specialized spray dried technology required in the manufacture of powdered IMF. The quality of our products continues to meet the highest international accreditation standards, which has enabled us to significantly increase our export base”, added Saad. Stavros Nicolaou Aspen Senior Executive Strategic Trade said: “Aspen’s objectives are entirely consistent and complimentary to Premier Makhura’s ten point economic growth plan of the province, which include re-industrialisation of the economy, creation of decent employment and the establishment of strategic partnerships” Aspen’s efforts to develop strategic partnerships for the supply of base powder further promotes trade and investment and supports the growth of key identified economic sectors in that it facilitates environmental sustainability and the efficient use of existing resources.

Aspen opposes violent attacks directed at fellow African migrants

Statement by Stephen Saad, Group CEO, Aspen Pharmacare Holdings Ltd “Aspen” on the violent attacks directed at fellow African migrants living in South Africa Durban – Aspen, largest producer and supplier of medicines to our African continent, in the strongest terms condemns the shameful and senseless harassment and violence directed at fellow African migrants, in KwaZulu Natal, Alexandra and other parts of our country. At this time we join many millions in our country, our continent and indeed around the world in conveying our heartfelt condolences to the families of those who lost their loved ones. Our thoughts also go out to those who have lost property and belongings and have subsequently been displaced to camps and other locations around our country. Accordingly Aspen was a leading part of the consultative stakeholder meeting on migrant Xenophobia convened by President Zuma and the Government of the Republic at the end of this week. At this meeting, some of Aspen’s proposals on addressing our country’s growing drug and substance abuse, one of the root causes identified by our Government of the problem was highlighted. To this end, Aspen will continue working with our Government and other civic organisations in assisting those who have been displaced and lost their belongings. On this basis, Aspen has made available a donation to enable procurement of much needed medicines for the camps, in order to contain the outbreak of diseases that has the potential to intensify this human tragedy. Furthermore, Aspen has undertaken together with other stakeholders, including Government, the sporting fraternity to co-ordinate a symbolic friendly soccer match, in which various leaders and both African and South African soccer legends will unite and send a strong message against Xenophobia. The aim is to host this match in Alexandra, the site of the senseless murder of Mozambican national Ernest Sithole, who died wearing a Bafana Bafana wrist band. Legally based African migrants are an integral part of our society and constitute a key part of the diversity that is the unique tapestry of our country. Those African migrants contribute much needed skills and intellectual capital to our economy. We acknowledge their contribution and call on all South Africans, the overwhelming majority of whom condemn Xenophobia to work together to re-establish an environment of tolerance, where all communities co-exist in peace and harmony. We must ensure these attacks are never repeated again. In closing, we call on all South Africans to support efforts at condemning Xenophobia, upholding the rule of Law and accelerating economic transformation and reducing inequality, all important aspects in ensuring an end to these deplorable attacks.

GSK announces completion of the sale of half its stake in Aspen

GlaxoSmithKline (“GSK”) has announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares). These shares were sold by means of an accelerated book build offering process which resulted in the shares being sold at ZAR 372 per share, raising gross proceeds of approximately ZAR 10.5 billion. Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital. Simon Dingemans, GSK’s Chief Financial Officer, said: “GSK has a long and successful commercial partnership with Aspen and our investment in the company has grown in value significantly over time. As we continue to reshape the Group around our core franchises and drive the benefits from the Novartis transaction, optimizing our financial flexibility to invest behind these priorities is key. As a result we have decided now is the right time to realise further value from this successful relationship. We continue to believe in the strategy of Aspen and we remain committed to working together in the future.” The Board of Aspen has agreed that Mr David Redfern, recently appointed as GSK’s nominee director to replace Mr Abbas Hussain on the Board, will remain a director of Aspen. Durban 13 March 2015 Sponsor: Investec Bank Limited ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 (“Aspen” or “the Company”)

We Care

Ethics & Compliance Management

SED Initiatives

Mandela Day

Our Sustainability Commitments

Working At Aspen

Bursary Applications

We Care

Ethics & Compliance Management

SED Initiatives

Mandela Day

Our Sustainability Commitments

Working At Aspen

Bursary Applications

Media Enquiries

Categories

Categories

Share on social

Follow on social

Our Purpose

Find out more

To improve the health and quality of life of patients.

Our Vision

Find out more

To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more

Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026. The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

View our teams below:

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.